The blurring of the boundary between higher-risk MDS and AML-MR observed in context of TET2 expression has been reiterated in the 2022 WHO classification of MDS (previously termed as ‘myelodysplastic syndromes’ and now renamed to ‘myelodysplastic neoplasms’) which mentions ‘any blast-based cut-off (for distinguishing MDS and AML) is arbitrary and cannot reflect the biologic continuity naturally inherent in myeloid pathogenic mechanisms’ [41]. The gene discussed is NR3C2; the disease is myelodysplastic syndrome.